“We are overwhelmed by the demand we have met in Sweden, from healthcare providers, authorities, companies and individuals. This also worries me, as it shows that the lack of protective medical equipment is widespread. We will therefore in the near term have to prioritize critical societal functions, such as health care providers and the police, as our production capacity is currently limited,” says Cecilia Edström, CEO.

“We are in close dialogue with the Government’s national coordinator for the life science industry and relevant authorities to secure the permits required to establish production in our home market as soon as possible. We see it as our obligation to help delay the spread of Covid-19 as much as possible and that socially critical functions can maintain their operations in this serious situation,” continues Cecilia Edström.

Bactiguard launched HYDROCYN aqua® in Sweden on March 12. The effect of HYDROCYN aqua® on coronaviruses has been tested and it is documented that it kills 99.9 percent of previous variants within 15–30 seconds. Previous experience also shows that the proven effect can be transferred to new variants of coronavirus. Tests on Covid-19 (SARS-CoV-2) are now underway to verify this.

HYDROCYN aqua® is a pH-neutral and water-based product used to date for wound care and, unlike alcohol and chlorhexidine, is not irritating, toxic or harmful to the body. The active substance is hypochlorous acid (HOCl). The product is CE marked (EU approved) and registered by the US FDA.

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2020-03-17, at 1.45 pm.

For further information, please contact:
Cecilia Edström, CEO, phone +46 440 58 80